Predicting cardiovascular events in patients with type 2 diabetes was the focus of multiple recent studies.
Three comparisons of bariatric surgery and medical management for obese type 2 diabetes patients were recently published in journals of the American Medical Association.
The annual meeting of the European Association for the Study of Diabetes was held in Barcelona, Spain in September. Research presented at the meeting covered risks of sulfonylureas, pioglitazone and macular edema, treatment intensification and
Recent studies looked at vitamin D supplementation, peer mentoring, and physician referrals to diabetes prevention programs among patients with prediabetes.
Two recent studies looked at cardiovascular disease (CVD) risk in women with type 2 diabetes, finding that fenofibrate may be associated with lowered risk and sulfonylureas with increased risk.
Recent trials examined the potential effects of probiotic supplements and sucrose octasulfate dressings.
Recent analyses of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial looked at the effects of fenofibrate on gout and cardiovascular events in patients with type 2 diabetes.
Recent evidence suggests it may improve the prognosis of patients with cancer (see the “Keeping tabs” section in this issue).
Several factors that increase or decrease one's risk of developing diabetes were identified by research released this month.
One recent study found that many patients with diabetes frequently forget to take their medications, while another analyzed the association between diabetes and brain volume and cognitive performance among older people.